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036 The Journal of Thoracic and Cardbjective: The effect of prosthesis–patient mismatch on clinical outcome and left
entricular mass regression after aortic valve replacement remains controversial.
ata on whether the clinical effect of prosthesis–patient mismatch depends on left
entricular function at the time of aortic valve replacement are lacking. This study
xamined the long-term clinical and echocardiographic effects of prosthesis–patient
ismatch in patients with and without left ventricular systolic dysfunction at the
ime of aortic valve replacement.
ethods: Preoperative and serial postoperative echocardiograms were performed in
05 adults who underwent aortic valve replacement between 1990 and 2003 and
ho were subsequently followed up in a dedicated valve clinic (follow-up, mean 
D, 5.5  3.5 years; maximum, 14.2 years). Preoperative left ventricular function
as defined as normal (ejection fraction 50%) in 548 patients and impaired
ejection fraction 50%) in 257 patients.
esults: Patients with impaired preoperative left ventricular function and prosthe-
is–patient mismatch (indexed effective orifice area0.85 cm2/m2) had a decreased
verall late survival (hazard ratio, 2.8; P  .03), decreased freedom from heart
ailure symptoms or heart failure death (odds ratio of 5.1 at 3 years after aortic valve
eplacement; P  .009), and diminished left ventricular mass regression compared
ith patients with impaired preoperative left ventricular function and no prosthesis–
atient mismatch. These effects of prosthesis–patient mismatch were not observed
n patients with normal preoperative left ventricular function.
onclusions: Prosthesis–patient mismatch at an indexed effective orifice area of
.85 cm2/m2 or less after aortic valve replacement primarily affects patients with
mpaired preoperative left ventricular function and results in decreased survival,
ower freedom from heart failure, and incomplete left ventricular mass regression.
atients with impaired left ventricular function represent a critical population in whom
rosthesis–patient mismatch should be avoided at the time of aortic valve replacement.
ortic valve replacement (AVR) prolongs life, improves symptoms of heart
failure, and induces regression of left ventricular hypertrophy in patients
with aortic stenosis or aortic insufficiency for whom an operation is
ndicated. However, controversy exists as to whether the ability of the replacement
rosthesis to allow unimpeded blood flow, a potentially modifiable parameter
elated to the size and type of prosthesis implanted at operation, influences the
ong-term outcome of patients undergoing AVR. The term prosthesis–patient mis-
atch (PPM) has been used to describe the phenomenon in which the effective
rifice area (EOA) of the implanted prosthesis may be inadequate for the patient’s
iovascular Surgery ● May 2006
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CDody size, potentially resulting in persistent left ventricular
utflow tract obstruction. In general, PPM has been defined
y a ratio of prosthetic EOA over patient body surface area
BSA), or indexed EOA, of 0.85 cm2/m2 or less1 and has
een observed in 19% to 70% of patients undergoing
VR.2,3 Smaller mismatch thresholds of 0.80 cm2/m2 or
ess, 0.75 cm2/m2 or less, and 0.65 cm2/m2 or less have been
roposed by some investigators.2,3
The effect of PPM on survival and left ventricular re-
odeling after AVR has been controversial. Although some
nvestigators have suggested that PPM results in decreased
arly and late survival after AVR,3,4 others have failed to
onfirm these findings.2,5-8 However, surgical selection fac-
ors confound this issue, because patients with PPM are
sually older, are more often female, are more often over-
eight, and have a higher prevalence of comorbidities than
hose without PPM.2,6 Two studies have examined the effect
f PPM on freedom from heart failure after AVR, and both
ave suggested a detrimental effect of PPM.2,9 There has
een conflicting evidence on the effect of PPM on left
entricular hypertrophy regression. Some investigators have
uggested that a small prosthesis does not impede left ven-
ricular remodeling,10-12 whereas others have observed de-
reased regression of left ventricular masses.13-15
The relief of aortic obstruction constitutes the main
echanism of clinical improvement and left ventricular
ass regression after AVR, and previous data have shown
hat preexisting left ventricular dysfunction impairs left
entricular mass regression after AVR.16 It is therefore
onceivable that PPM may affect clinical outcome and left
entricular mass regression in patients with abnormal left
entricular function differently than in those with normal
eft ventricular function. A recent article suggested that the
arly perioperative effect of PPM is especially significant in
atients with preoperative left ventricular dysfunction.3 To
ate, however, no study has examined the effect of preop-
rative left ventricular function on the medium- and long-
erm outcome of patients with PPM after AVR. Thus, the
urpose of this study was to investigate whether the effect
f PPM on medium- and long-term survival, freedom from
eart failure, and left ventricular mass regression is affected
y preoperative left ventricular function in patients under-
Abbreviations and Acronyms
AVR  aortic valve replacement
BSA  body surface area
CI  confidence interval
EOA  effective orifice area
LVEF left ventricular ejection fraction
PPM  prosthesis–patient mismatchoing AVR. c
The Journal of Thoracicethods
atient Population and Clinical Follow-up
he patient population consisted of all adult patients (n  805)
ho underwent AVR at the University of Ottawa Heart Institute
etween 1990 and 2003 with a prosthesis that is still commercially
vailable in North America, who survived the operation, and who
ere followed up annually in a dedicated valve clinic. Patients
ho underwent concomitant mitral valve repair or replacement
ere excluded. At each clinic visit, patients had a history focused
n the determination of functional status and the occurrence of
alve-related complications, physical examination, electrocardio-
ram, chest radiograph, complete blood count, serum chemistries,
nd international normalized ratio determinations (when applica-
le). The total follow-up was 3285 patient-years, with a mean
SD) duration of 5.5  3.5 years (range, 60 days to 14.2 years).
ll patients were followed up for at least 1 outpatient visit.
Patients received anticoagulation treatment according to guide-
ines in effect at the time, as previously described.17 Persistence or
ecurrence of heart failure after AVR was defined as the composite
nd point of (1) New York Heart Association functional class III
r IV symptoms for more than 4 consecutive weeks or (2) death for
hich the primary or contributing diagnosis was congestive heart
ailure.2,3 Clinical impressions were corroborated with physical
xamination, chest radiograph, electrocardiogram, and echocardio-
raphic findings. Persistent postoperative hypertension was de-
ned as a systemic blood pressure greater than 140/90 mm Hg for
or more follow-up visits. Prosthesis-related complications were
ecorded according to the “Guidelines for Reporting Morbidity and
ortality after Cardiac Valvular Operations.”18
rostheses
rosthesis type and size were recorded for all patients. Prostheses
ere implanted and oriented according to the manufacturer’s in-
tructions. The prostheses used were the Medtronic Hancock II
Medtronic, Inc, Minneapolis, Minn) in 223 patients (28%), St
ude Medical Standard (St Jude Medical, Inc, St Paul, Minn) in
51 patients (19%), Carbomedics (Sulzer CarboMedics, Inc, Aus-
in, Tex) in 137 patients (17%), Medtronic Hall in 89 patients
11%), homograft in 58 patients (7%), Medtronic Hancock I in 47
atients (6%), St Jude Medical HP in 45 patients (6%), Edwards
ERIMOUNT (Edwards Lifesciences, Irvine, Calif) in 38 patients
5%), MCRI On-X (Medical Carbon Research Institute, Austin,
ex) in 8 patients (1%), stentless porcine in 5 patients (0.6%), and
arpentier-Edwards Standard in 4 patients (0.5%).
The in vivo EOA for each prosthesis type and size was obtained
rom the literature from patients with normally functioning pros-
heses1 and averaged if more than 1 published value was available.
his was supplemented with data provided by the valve manufac-
urer if published data were insufficient with respect to a specific
rosthesis size.
The indexed EOA was obtained by dividing the in vivo EOA
y the patient’s BSA at the time of operation and was available for
ll patients. PPM was defined as an indexed EOA of 0.85 cm2/m2
r less for the purpose of examining clinical and echocardio-
raphic outcomes. In addition, echocardiographic outcomes were
xamined at mismatch thresholds of 0.80 cm2/m2 or less and 0.75
m2/m2 or less.
and Cardiovascular Surgery ● Volume 131, Number 5 1037
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A
CDchocardiography Follow-up
atients underwent a complete M-mode, 2-dimensional, and Doppler
ransthoracic echocardiogram before AVR and underwent serial
chocardiographic examinations on a biannual basis or as clini-
ally indicated after AVR. Left ventricular end-diastolic and end-
ystolic diameters, septum and posterior wall thicknesses, and left
trial anteroposterior diameters were measured from the M-mode
ecordings according to the recommendations of the American
ociety of Echocardiography.19 Left ventricular mass was calcu-
ABLE 1. Patient characteristics
ariable
Normal left
No mismatch
(n  315)
emale sex 96 (30.5%)
ge at operation (y) 58.5 14.0
ody surface area (m2) 1.81 0.24
YHA class
I 90 (28.6%)
II 103 (32.7%)
III 81 (25.7%)
IV 41 (13.0%)
eft ventricular grade*
1 315 (100%)
2 0
3 0
4 0
nd-diastolic diameter (cm) 5.1 0.6
nd-systolic diameter (cm) 3.0 0.6
oronary artery disease 80 (25.4%)
trial fibrillation 30 (9.5%)
revious aortic valve replacement 63 (20.0%)
perative indication for aortic stenosis 234 (74.3%)
ean preoperative AVA (cm2) 0.74 0.19
ioprosthetic valve implant 76 (24.1%)
ortic annulus or root enlargement† 33 (10.5%)
ismatch stands for prosthesis–patient mismatch, defined as a ratio of th
o or less than 0.85 cm2/m2. P values refer to the comparison between mism
unction groups. Data are mean  SD or n (%). NYHA, New York Heart As
jection fraction of 50% or more; grade 2, ejection fraction of 40% to 49%;
0%. †Consists of annular (Nicks, Manouguian, Konno) or aortic root enlaated by using the modified formula of the American Society of a
038 The Journal of Thoracic and Cardiovascular Surgery ● Machocardiography.20 Left ventricular ejection fraction (LVEF) was
uantified by visual estimation by 1 or more of 4 blinded observ-
rs.21 Left ventricular systolic function was graded as 1, normal
LVEF 50%); 2, mildly impaired (LVEF 40%-49%); 3, moder-
tely impaired (LVEF 30%-39%); or 4, severely impaired (LVEF
30%). To assess the effect of preoperative left ventricular func-
ion on the effect of PPM, patients were divided into those with
ormal (LVEF 50%) and impaired (LVEF 50%) left ventric-
lar systolic function. Peak instantaneous and mean transvalvular
icular function Impaired left ventricular function
Mismatch
(n  233)
No mismatch
(n  165)
Mismatch
(n  92)
113 (48.5%) 36 (21.8%) 25 (27.2%)
P  .001 P  .3
70.8 10.2 60.2  12.9 71.5 11.5
P  .001 P  .001
1.94 0.22 1.81 0.22 1.95 0.22
P  .001 P  .001
57 (24.5%) 27 (16.4%) 21 (22.8%)
60 (25.8%) 40 (24.2%) 17 (18.5%)
81 (34.8%) 61 (37.0%) 39 (42.4%)
35 (15.0%) 37 (22.4%) 15 (16.3%)
P  .1 P  .3
233 (100%) 0 0
0 82 (49.7%) 43 (46.7%)
0 51 (30.9%) 31 (33.7%)
0 32 (19.4%) 18 (19.6%)
P  NA P  .9
5.0  0.6 6.0 0.8 5.9  0.9
P  .1 P  .3
2.9  0.6 4.5 1.0 4.4  0.9
P  .4 P  .5
87 (37.3%) 56 (33.9%) 45 (48.9%)
P  .003 P  .02
32 (13.7%) 23 (13.9%) 17 (18.5%)
P  .1 P  .3
33 (14.2%) 28 (17.0%) 10 (10.9%)
P  .1 P  .2
201 (86.3%) 101 (61.2%) 79 (85.9%)
P  .001 P  .001
0.75 0.73 0.73 0.24 0.70 0.21
P  .8 P  .3
183 (78.5%) 33 (20.0%) 79 (85.9%)
P  .001 P  .001
25 (10.7%) 13 (7.9%) 7 (7.6%)
P  .9 P  .9
sthesis’s effective orifice area over the patient’s body surface area equal
and no-mismatch patients within the normal and impaired left ventricular
tion; NA, not applicable; AVA, aortic valve area. *Grade 1, left ventricular
3, ejection fraction of 30% to 39%; grade 4, ejection fraction of less than
ent using pericardium or Dacron.ventr
e pro
atch
socia
gradend transprosthesis pressure gradients were derived by modified
y 2006
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A
CDernoulli equations, and the preoperative aortic valve EOA was
alculated with the continuity equation.22
tatistical Analyses
ata were imported and analyzed in Intercooled Stata 8 (Stata
orp, College Station, Tex). Continuous data are presented as
ean  SD or mean (lower 95% confidence limit, upper 95%
onfidence limit).
Survival. Potential predictors of survival, including left ven-
0
25
50
75
100
0 5 10
Interval (years) after Aortic Valve Replacement
%
 S
u
rv
iv
al
 (
cr
u
d
e)
Normal LV; No PPM
Impaired LV; No PPM
Normal LV; PPM
Impaired LV; PPM
0
25
50
75
100
0 5 10
Interval (years) after Aortic Valve Replacement
%
 S
u
rv
iv
al
 (
ad
ju
st
ed
)
Normal LV; No PPM
Impaired LV; No PPM
Normal LV; PPM
Impaired LV; PPM
Number of Patients at Risk: 
315  122 22 Normal LV; No PPM
165 71 14 Impaired LV; No PPM
233 65 10 Normal LV; PPM
92 17 3 Impaired LV; PPM
Adjusted HR* BC 95% CI       P value
Impaired LV; No PPM: 1.2 0.5, 2.2              0.5
Normal LV; PPM: 1.6 0.7, 3.8              0.3
Impaired LV; PPM: 2.6 1.1, 7.8              0.02
Crude HR* 95% CI          P value
Impaired LV; No PPM: 1.4 0.7, 2.8              0.4
Normal LV; PPM: 2.0 1.0, 3.8              0.04
Impaired LV; PPM: 3.8 1.8, 8.0            <0.001
igure 1. Crude (A) and adjusted (B) survival after aortic valve
eplacement, by left ventricular function and prosthesis–patient
ismatch. Patients with the combination of impaired preopera-
ive left ventricular function and postoperative prosthesis–patient
ismatch had lower survival after aortic valve replacement,
espite adjustment for age, other risk factors for mortality after
VR,2 and baseline patient characteristics. *Crude and adjusted
azard ratios are in comparison to the “Normal LV; No PPM”
roup. CI, Confidence interval; HR, hazard ratio; LV, left ventricle;
PM, prosthesis–patient mismatch.ricular function and PPM indicators, were tested for equality with w
The Journal of Thoraciclog-rank test. For multivariate models, the proportional hazard
ssumption was tested with generalized Cox-Snell residuals. If the
ssumption was met, Cox proportional hazards models were de-
eloped (1) by incorporating variables that had a P value of .05
r less on log-rank testing; (2) by forcing into models the risk
actors for decreased survival after AVR identified previously2 (ie,
ge, atrial fibrillation, preoperative heart failure functional class,
oronary artery disease, smoking, and insulin-dependent diabetes
ellitus); and (3) by incorporating into the model patient charac-
eristics that differed between the mismatch and no-mismatch
roups. To account for confounding, no automated model selection
rocedure was used, and all covariates were used simultaneously.
roportional hazards models were subjected to 100 bootstrap rep-
ications, as previously described,2 and estimates of standard error,
ias, and 95% confidence intervals (CIs) were derived from the
00 replications by using a bias-corrected method.
Heart failure. The effects of left ventricular dysfunction and
PM on the cumulative incidence of heart failure symptoms or
eart failure–related death within 3 years after AVR were exam-
ned by logistic regression. A 3-year period was arbitrarily chosen
o allow maximal symptom improvement and left ventricular re-
odeling in the greatest potential number of cohort patients2,23
igure 2. Effect of preoperative left ventricular function and pros-
hesis–patient mismatch on the cumulative incidence of heart
ailure symptoms or death related to heart failure at 3 years after
ortic valve replacement. Nonitalic percentages, bars, and odds
atios refer to the occurrence of either heart failure symptoms or
eath. Italic percentages in parentheses indicate heart failure
eath. Odds ratios are in comparison to the “Normal LV; No PPM”
roup and are adjusted for risk factors of decreased freedom from
eart failure after AVR2 and for baseline patient characteristics.
atients with the combination of impaired preoperative left ven-
ricular function and postoperative prosthesis–patient mismatch
ad a lower freedom from heart failure despite adjustment for
onfounding factors. CI, Confidence interval; LV, left ventricle;
PM, prosthesis–patient mismatch.hile minimizing the possible confounding effects of early struc-
and Cardiovascular Surgery ● Volume 131, Number 5 1039
t
r
f
a
(
n
t
e
o
a
m
c
g
t
m
p
l
r
t
u
R
P
T
T
0
o
o
a
p
f
m
a
“
N
V
B
v
P
3
m
S
n
t
v
m
r
s
f
m
p
1
m
d
t
a
2
8
S
F
c
t
c
t
A
T
V
C
R
I
I
M
9
n
d
s specifi
Surgery for Acquired Cardiovascular Disease Ruel et al
1
A
CDural valve deterioration on heart failure symptoms.24 Logistic
egression models incorporated (1) the risk factors for decreased
reedom from heart failure after AVR identified previously2 (ie,
ge, atrial fibrillation, coronary disease, and redo AVR status), and
2) patient characteristics that differed between the PPM and
o-PPM groups.
Left ventricular mass regression. Echocardiographic left ven-
ricular mass changes were derived from the lowest postoperative
chocardiographically derived left ventricular mass minus the pre-
perative left ventricular mass. These changes were expressed in
bsolute fashion in relation to the preoperative left ventricular
ass and indexed to the patient’s baseline BSA. Changes were
ompared between PPM and no-PPM patients within the 2 sub-
roups of normal and impaired preoperative left ventricular func-
ion by using an analysis of variance. Bonferroni corrections for
ultiple tests were applied as appropriate. In addition, the inde-
endent effect of PPM on left ventricular mass regression within a
eft ventricular function subgroup was examined by using linear
egression models that also incorporated age, sex, and postopera-
ive hypertension as potential confounders of altered left ventric-
lar mass regression.25,26
esults
atient Characteristics
he preoperative characteristics of the cohort are shown in
able 1. Patients with PPM defined as an indexed EOA of
.85 cm2/m2 or less were significantly older, were more
ften female, had a larger BSA, had a higher coprevalence
f coronary artery disease, were more often operated on for
ortic stenosis, and more often received a bioprosthesis than
atients without PPM. Consequently, these variables were
orced into the multivariate regression models that esti-
ated survival, heart failure, and left ventricular mass in
ddition to the other a priori covariates described in the
ABLE 2. Postoperative left ventricular mass regression at
ariable No mismatch
hange in LV mass (g)* 60 (69, 50)
elative change in LV mass (% of
preoperative LV mass)
20% (24, 17)
ndexed change in LV mass (g/m2 of BSA) 33 (39,28)
ndexed change in LV mass regression
coefficient (g/m2 of BSA)†
NA
ismatch threshold values represent the prosthesis’s effective orifice area
5% confidence limit, upper 95% confidence limit). P values refer to the c
o-mismatch patients. LV, Left ventricular; BSA, body surface area; NA, n
erived left ventricular mass minus the preoperative left ventricular mass.
ex, postoperative hypertension, and prosthesis–patient mismatch at theStatistical Analyses” section. s
040 The Journal of Thoracic and Cardiovascular Surgery ● Maative Aortic Valve and Prosthetic
alve Hemodynamics
efore surgery, the peak and mean instantaneous trans-
alvular pressure gradients were similar in patients with
PM compared with those without PPM (peak, 76.4 
0.3 mm Hg vs 72.4  34.6 mm Hg; mean, 45.3  18.9
m Hg vs 42.5  21.8 mm Hg, respectively; P  .1).
ignificantly higher preoperative peak and mean instanta-
eous transvalvular pressure gradients were observed in pa-
ients with normal compared with impaired preoperative left
entricular function (peak, 77.2 33.6 mm Hg vs 67.2 30.3
m Hg; mean, 45.4  21.2 mm Hg vs 40.0  18.9 mm Hg,
espectively; P  .002). Preoperative aortic valve EOA was
imilar in patients with normal and impaired left ventricular
unction (0.76  0.63 cm2 vs 0.72  0.25 cm2; P  .4).
After surgery, patients with PPM had higher peak and
ean instantaneous transprosthesis gradients compared with
atients with no PPM (peak, 32.3  16.3 mm Hg vs 27.3 
3.6 mm Hg; mean, 17.8  9.5 mm Hg vs 14.7  7.6
m Hg, respectively; P  .001). There was no significant
ifference in postoperative peak and mean instantaneous
ransprosthesis gradients between patients with normal
nd impaired preoperative left ventricular function (peak,
9.8  15.1 mm Hg vs 27.8  14.4 mm Hg; mean, 16.1 
.4 mm Hg vs 15.4  8.8 mm Hg, respectively; P  .1).
urvival
igure 1 displays the crude and adjusted survival of the total
ohort according to the preoperative left ventricular func-
ion and the presence of PPM after AVR. Patients with the
ombination of impaired preoperative left ventricular func-
ion and postoperative PPM had decreased survival after
VR, both crude (Figure 1, A) and after adjustment for age,
easing degrees of prosthesis–patient mismatch, according
Normal left ventricular function
Mismatch
<0.85 cm2/m2
Mismatch
<0.80 cm2/m2
Mismatch
<0.75 cm2/m2
57 (67, 47) 57 (67, 46) 68 (80, 55)
P  .7 P  .7 P  .1
22% (26, 19) 24% (28, 20) 27% (32, 23)
P  .3 P  .2 P  .1
29 (34, 24) 28 (33, 23) 34 (40, 27)
P  .3 P  .3 P  .5
1 (9, 7) 0.4 (8, 9) 8 (17, 1)
P  .8 P  .9 P  .1
ed by the patient’s body surface area. Data are expressed as mean (lower
rison between prosthesis–patient mismatch (at the specified degree) and
plicable. *Calculated as the lowest postoperative echocardiographically
ivariate linear regression models include as simultaneous covariates age,
ed degree.incr
divid
ompa
ot ap
†Multex, atrial fibrillation, preoperative heart failure functional
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A
CDlass, coronary artery disease, smoking, insulin-dependent
iabetes mellitus, predominant valve lesion at operation,
nd use of a bioprosthesis (Figure 1, B). An independent
eath hazard ratio of 2.6 (bias-corrected 95% CI, 1.1-7.8;
 .02) was observed in patients with impaired left ven-
ricular function and PPM compared with patients with
ormal left ventricular function and no PPM. Furthermore,
death hazard ratio of 2.8 (95% CI, 1.1-8.0; P  .03) was
bserved in patients with impaired left ventricular function
nd PPM compared with patients with impaired left ven-
ricular function and no PPM. In contrast, there was no
ifference in crude or adjusted survival between patients
ith normal preoperative left ventricular function and PPM
ersus patients with normal preoperative left ventricular
unction and no PPM (hazard ratio, 1.6; 95% CI, 0.7-3.8;
 .3).
eart Failure
he combination of impaired preoperative left ventricular
unction and postoperative PPM had a negative effect on
reedom from heart failure at 3 years after AVR (Figure 2).
his was seen both on univariate analyses and after adjust-
ent for age, sex, atrial fibrillation, coronary disease, pre-
ominant valve lesion at operation, use of a bioprosthesis,
nd redo AVR. The adjusted odds ratio for heart failure at
years after AVR in patients with the combination of
mpaired preoperative left ventricular function and postop-
rative PPM was 5.1 (95% CI, 1.5-17; P  .009). In no
ther subgroup defined by preoperative left ventricular
unction or PPM was a significant increase in the cumula-
ive incidence of heart failure observed.
eft Ventricular Mass Regression
atients with impaired left ventricular systolic function and
to preoperative left ventricular function
Impaired left v
No mismatch
Mismatch
<0.85 cm2/m2
93 (112,75) 57 (75, 39)
P  .01
25% (30, 21) 16% (22, 11)
P  .03
52 (63, 41) 30 (40, 20)
P  .01
NA 17 (0,34)
P  .05PM demonstrated less left ventricular mass regression t
The Journal of Thoracicompared with patients with impaired left ventricular sys-
olic function without PPM (Table 2). This detrimental
ffect was greater as PPM became more severe and was
bserved for the absolute change in left ventricular mass,
he relative change in left ventricular mass as a percentage
f preoperative left ventricular mass, and the change in left
entricular mass indexed for BSA. The multivariate regres-
ion coefficient for the change in left ventricular mass
ndexed for BSA, adjusted for patient characteristics and the
resence of persistent hypertension during postoperative
ollow-up, was also significantly reduced in patients with
mpaired left ventricular systolic function and PPM and
ndependently demonstrated less mass regression as the
everity of PPM increased. In contrast, left ventricular mass
egression, as assessed by the absolute change in left ven-
ricular mass, the relative change in left ventricular mass as
percentage of preoperative left ventricular mass, or the
hange in left ventricular mass indexed for BSA, was not
ignificantly different between PPM and non-PPM patients
ith normal preoperative left ventricular systolic function.
iscussion
he concept of PPM was first introduced by Rahimtoola27
n 1978 as a condition in which the in vivo EOA of the
ortic prosthetic valve is less than that of the native human
alve. Subsequent work from numerous groups over the
ears has yielded contradictory results with respect to the
ffect of PPM on late survival, clinical outcome, and left
entricular mass regression after AVR.2-14 The main finding
f this study is that PPM primarily affects patients with
mpaired left ventricular function at the time of AVR. In-
ependent detrimental effects of PPM were observed only
n patients with impaired preoperative left ventricular sys-
cular function
Mismatch
<0.80 cm2/m2
Mismatch
<0.75 cm2/m2
47 (69, 27) 36 (57, 16)
P  .005 P  .002
14% (21, 8) 12% (20, 4)
P  .009 P  .008
25 (36, 14) 18 (29, 8)
P  .004 P  .002
21 (1, 40) 26 (4, 47)
P  .03 P  .02entriolic function, in whom PPM was associated with decreased
and Cardiovascular Surgery ● Volume 131, Number 5 1041
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CDverall long-term survival, lower freedom from heart fail-
re, and diminished left ventricular mass regression. Pa-
ients with PPM and impaired left ventricular systolic func-
ion at the time of AVR have a greater than twofold increase
n the risk of late death, a fivefold increase in the cumulative
ncidence of heart failure by 3 years, and approximately
0% less left ventricular mass regression compared with
atients with left ventricular dysfunction and no PPM. Fur-
hermore, the amount of left ventricular mass regression
ecreases with increasing severity of PPM in patients with
mpaired preoperative left ventricular function. Thus, in
atients with left ventricular dysfunction at the time of
VR, there seems to be a minimal threshold in prosthesis
ize, near an indexed EOA of 0.85 cm2/m2, beyond which
urvival and cardiac recovery may not reach their maximum
otential after valve replacement. PPM at or beyond this
hreshold should therefore be avoided in patients with pre-
xisting left ventricular dysfunction.
Conversely, our data also demonstrate that PPM at a
hreshold of 0.85 cm2/m2 or less does not result in signifi-
ant detrimental effects on overall long-term survival, free-
om from heart failure, and left ventricular mass regression
n patients with normal preoperative left ventricular func-
ion. Thus, special techniques other than optimized prosthe-
is selection based on hemodynamics that are used to avoid
ismatch and that may occasionally be associated with
dditional operative risk, such as the use of aortic root
nlargement or the implantation of a stentless valve, do not
eem justified solely on the basis of potential improvement
n late outcome in patients with normal left ventricular
unction and a predicted indexed EOA of less than 0.85
m2/m2 at the time of AVR. However, because this study
xamined only common mismatch thresholds and did not
valuate very severe mismatch, such as 0.65 cm2/m2 or less
a value occasionally chosen by other investigators),3 we
annot comment on whether more severe PPM might in turn
ead to a significant late clinical or echocardiographic effect
n patients with normal left ventricular function.
Recently, Blais and colleagues3 suggested that the early
erioperative clinical effect of PPM may be most significant
n patients with preoperative left ventricular dysfunction.
hese investigators observed a 3.7-fold increase in the
0-day mortality rate in patients with PPM and a left ven-
ricular ejection fraction of less than 40% compared with
atients with PPM and an ejection fraction greater than
0%. Patients with PPM and a preoperative left ventricular
jection fraction less than 40% had a 77.1 relative risk ratio
or mortality at 30 days compared with an 11.3 relative risk
atio for patients with PPM and a left ventricular ejection
raction of 40% or more. To our knowledge, no study to
ate has evaluated the medium- and long-term effect of
PM after AVR on the basis of the preoperative left ven-ricular function and separately analyzed patients with nor- d
042 The Journal of Thoracic and Cardiovascular Surgery ● Maal versus impaired left ventricular function. Our data
xpand on the observations of Blais and colleagues and
emonstrate that PPM at a threshold of 0.85 cm2/m2 or less
ecreases long-term survival and freedom from heart failure
nd impairs left ventricular mass regression beyond the
erioperative period in patients with impaired preoperative
eft ventricular function, but not in patients with normal
reoperative left ventricular function. It is possible that the
nteraction between PPM and preoperative left ventricular
unction identified in this study may have accounted in part
or the often-conflicting observations on the effect of PPM
n previous studies.
This study examined the outcome of patients who sur-
ived AVR and did not focus on early perioperative out-
omes, in order to evaluate left ventricular mass regression
nd heart failure symptoms, which cannot be adequately
valuated in the perioperative period. Furthermore, surgical
ecision making and confounding by indication may espe-
ially bias perioperative outcomes in patients with PPM,
ecause surgeons may tend to avoid the more complex
peration required to implant a larger prosthesis and avoid
ismatch in patients with poor physical condition and sig-
ificant comorbidity who are at higher baseline operative
isk, thus resulting in an apparent increase in perioperative
ortality in patients receiving a smaller prosthesis. This
otential perioperative bias may therefore have been mini-
ized by our study design.
imitations
ur study used the indexed in vivo EOA values derived
rom normally functioning valves rather than prosthesis size
o determine the presence of PPM after AVR.1 The use of
ther indices, such as prosthesis label size, which is not
tandardized, or geometric internal orifice area, which does
ot account for the many characteristics of a valve that may
ontribute significantly to the EOA (such as prosthesis
eight, profile, opening angle, and leaflet inertia), may have
layed a role in the discrepancies between studies that have
xamined the effect of PPM. Using the EOA derived by the
oppler-echo continuity equation in individual patients af-
er prosthesis implantation might have better quantified the
egree of PPM; however, this method also has several
imitations related to difficulties of accurately measuring the
eft ventricular outflow diameter caused by reverberations
rom the prosthetic valve and the presence of large localized
ransprosthetic gradients and nonflat transprosthetic spatial
elocity profiles, which frequently result in large discrep-
ncies between Doppler-echo and actual EOA measure-
ents.28-30 Furthermore, the EOA derived from individual
atients has a major drawback because it is not available at
he time of surgical decision making and therefore cannot
elp to avoid PPM during the operation. This EOA can be
etermined only once the prosthesis has been inserted, the
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A
CDatient has been weaned from cardiopulmonary bypass, and
he preload, afterload, and contractility have normalized.
herefore, the EOA of an individual patient has little or no
ole in predicting whether PPM will be avoided by using a
iven prosthesis and size and whether another prosthesis or
ize should be selected and/or aortic root enlargement be
erformed before implantation. It is important to note that
PM, as defined in this study by using the in vivo EOA, was
trongly predictive of early and late postoperative transpros-
hesis gradients, thus suggesting that our methodology ac-
urately reflected aortic root hemodynamics in individual
atients.
Previous myocardial infarction is difficult to rule out
ith certainty in patients with severe valvular disease, cor-
nary artery disease, and left ventricular dysfunction. Con-
equently, it was not always possible to establish the exact
nderlying etiology of left ventricular dysfunction in af-
ected patients of this cohort, even though the coprevalence
f coronary artery disease at baseline was adjusted for in the
ultivariate analyses. It is possible that the underlying
echanism of left ventricular dysfunction in affected pa-
ients may have varied between the mismatch and no-
ismatch groups in a proportion that was different from that
f their respective coprevalence of coronary disease, and, if
o, this could have confounded the results. Furthermore, the
ndings of this study, as with any large observational co-
ort, may not necessarily be generalizable to all patients
ith prosthetic valves, because it represents a single insti-
ution’s experience and may have been affected by referral
nd patient care patterns.
onclusions
he effect of PPM on left ventricular mass regression,
reedom from heart failure, and survival in patients after
VR is dependent on preoperative left ventricular func-
ion. Patients with PPM and left ventricular systolic
ysfunction have a greater than twofold increase in the
isk of late death, a fivefold increase in the cumulative
ncidence of heart failure by 3 years, and incomplete left
entricular mass regression compared with patients with
eft ventricular dysfunction and no PPM. In contrast, the
resence of PPM at a threshold of 0.85 cm2/m2 or less in
atients with normal left ventricular function at the time
f AVR was not associated with a significant increase in
ate adverse events. The results of this study suggest that
mplantation of an aortic valve prosthesis with an esti-
ated indexed EOA of 0.85 cm2/m2 or less should be
voided in patients with a preoperative LVEF of less than
0%. Patients with impaired left ventricular function
epresent a critical population in whom special technical
teps or careful prosthesis selection based on hemody-
amics should be performed at the time of AVR to avoid
The Journal of Thoracicostoperative PPM and to potentially improve long-term
utcomes.
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